[Post-menopausal osteoporosis : physiopathology and therapy (author's transl)].
Though directly related to the estrogen levels deficiency during the menopause, post-menopausal osteoporosis, which represents 80 % of presenile osteoporosis cases, are very unequally affecting women. A rich bone system and high residual blood estrogen levels are two essential factors for preventing this invalidating affection, especially if the woman continues to lead an active physical life and to take a diet which includes a balanced intake of calcium. Women "at risk" will benefit from administration of estrogen progestogen therapy as early as possible after the menopause onset, as long as no contra-indications to this treatment will take place and that it is administered under close supervision.
D000368:Aged; D002116:Calcitonin / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D010024:Osteoporosis / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy; D005082:Physical Exertion; D014807:Vitamin D / Q000627:therapeutic use
D004967:Estrogens; D014807:Vitamin D; D002116:Calcitonin; D002118:Calcium
Physiopathologie de l'ostéoporose post-ménopausique. Considérations thérapeutiques.